Tearsheet
CLRB Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About CLRB Interactive Breakdown Better Bets vs. CLRB Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Investor Videos Industry Resource Links External Quote Links

Cellectar Biosciences (CLRB)

Market Price (6/19/2026): $2.68 | Market Cap: $11.4 MilSector: Health Care | Industry: Biotechnology

Cellectar Biosciences (CLRB)

Market Price (6/19/2026): $2.68
Market Cap: $11.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -58%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -166%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -22 Mil

Stock price has recently run up significantly
12M Rtn12 month market price return is 663%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -181%

High stock price volatility
Vol 12M is 3159%

Key risks
CLRB key risks include [1] a significant funding shortfall and "going concern" warning, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -58%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -166%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -22 Mil
5 Stock price has recently run up significantly
12M Rtn12 month market price return is 663%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -181%
7 High stock price volatility
Vol 12M is 3159%
8 Key risks
CLRB key risks include [1] a significant funding shortfall and "going concern" warning, Show more.

CLRB in ETFs

Weight = CLRB's share of each fund

VTI0.00%

Valuation & Metrics

FYE: 12/31CLRB [1]S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]$0.0 Mil—
FY 2026 Sales$3.8 Mil—
FY 2027 Sales$6.8 Mil—
FY 2026 Sales Growth——
FY 2027 Sales Growth78.0%7.7%
EARNINGS
LTM Net Income (GAAP) [3]$-20.8 Mil—
FY 2026 Net Income (Non-GAAP)$-5.3 Mil—
FY 2027 Net Income (Non-GAAP)$-4.2 Mil—
FY 2027 Net Income Growth—15.0%
FY 2026 EPS (Non-GAAP)$-2.05—
FY 2027 EPS (Non-GAAP)$-1.60—
FY 2027 EPS Growth——
VALUATION
FY 2026 P/S3.03.2
FY 2027 P/S1.7—
FY 2026 P/E—20.5
FY 2027 P/E——

[1] CLRB forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).
null

AI Analysis | Feedback

MetricValueDateSource
Number of Employees1112312024Link
Number of Product Candidates in Pipeline512102024Link
Planned enrollment for Phase 1b CLR 125 trial756262025Link
Number of Recent Patents Granted410022023Link

Price Chart

null
Upcoming
8/13/2026Earnings ReleaseRev: $12 Mil (E)
EPS: $-0.47 (E)

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/18/2026

Cellectar Biosciences (CLRB) stock has lost about 15% since 2/28/2026 because of the following key factors:

1. Dilution from May 2026 Financing.

Cellectar Biosciences completed an oversubscribed financing in May 2026, raising up to $140 million, with net proceeds of approximately $31 million upfront. While this financing extends the company's cash runway into fiscal Q2 2027, the issuance of new equity or convertible securities to raise this capital likely contributed to dilution for existing shareholders, placing downward pressure on the stock price.

2. Continued Pre-Revenue Status and Investor Caution Regarding Cash Burn.

In its fiscal Q1 2026 earnings reported on May 14, 2026, Cellectar Biosciences, a clinical-stage company, reported no revenue. Despite beating analyst estimates for net loss by reporting -$1.33 per share against a consensus of -$1.78 to -$1.92, investor sentiment remained cautious, with shares declining modestly after the announcement. This reaction indicates ongoing concerns about the company's cash burn and the absence of near-term revenue catalysts, which are typical challenges for pre-commercial biotechnology firms.

Show more
Updated on 6/18/2026

Cellectar Biosciences (CLRB) stock has lost about 15% since 2/28/2026 because of the following key factors:

1. Dilution from May 2026 Financing.

Cellectar Biosciences completed an oversubscribed financing in May 2026, raising up to $140 million, with net proceeds of approximately $31 million upfront. While this financing extends the company's cash runway into fiscal Q2 2027, the issuance of new equity or convertible securities to raise this capital likely contributed to dilution for existing shareholders, placing downward pressure on the stock price.

2. Continued Pre-Revenue Status and Investor Caution Regarding Cash Burn.

In its fiscal Q1 2026 earnings reported on May 14, 2026, Cellectar Biosciences, a clinical-stage company, reported no revenue. Despite beating analyst estimates for net loss by reporting -$1.33 per share against a consensus of -$1.78 to -$1.92, investor sentiment remained cautious, with shares declining modestly after the announcement. This reaction indicates ongoing concerns about the company's cash burn and the absence of near-term revenue catalysts, which are typical challenges for pre-commercial biotechnology firms.

3. Profit-Taking After Initial Spikes from Positive Clinical Data.

On May 5, 2026, Cellectar Biosciences announced positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial, showing an 83.6% overall response rate and a 61.8% major response rate for iopofosine I-131 in Waldenström Macroglobulinemia patients. This news, coupled with the financing announcement, initially drove the stock up over 27%. However, the subsequent decline in share price suggests that the market engaged in profit-taking following this positive catalyst, indicating that while the data was promising, the long timeline to regulatory approval and commercialization tempered sustained upward momentum.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -14.0% change in CLRB stock from 2/28/2026 to 6/18/2026 was primarily driven by a -25.4% change in the company's Shares Outstanding (Mil).
(LTM values as of)22820266182026Change
Stock Price ($)3.252.79-14.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)34-25.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/18/2026
ReturnCorrelation
CLRB-14.0% 
Market (SPY)9.2%29.5%
Sector (XLV)-6.4%7.1%

Fundamental Drivers

The -22.3% change in CLRB stock from 11/30/2025 to 6/18/2026 was primarily driven by a -25.4% change in the company's Shares Outstanding (Mil).
(LTM values as of)113020256182026Change
Stock Price ($)3.592.79-22.3%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)34-25.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/18/2026
ReturnCorrelation
CLRB-22.3% 
Market (SPY)9.9%26.7%
Sector (XLV)-4.4%3.0%

Fundamental Drivers

The -63.5% change in CLRB stock from 5/31/2025 to 6/18/2026 was primarily driven by a -63.8% change in the company's Shares Outstanding (Mil).
(LTM values as of)53120256182026Change
Stock Price ($)7.652.79-63.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)24-63.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/18/2026
ReturnCorrelation
CLRB-63.5% 
Market (SPY)28.1%9.0%
Sector (XLV)14.6%8.2%

Fundamental Drivers

The -94.0% change in CLRB stock from 5/31/2023 to 6/18/2026 was primarily driven by a -91.1% change in the company's Shares Outstanding (Mil).
(LTM values as of)53120236182026Change
Stock Price ($)46.802.79-94.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)04-91.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/18/2026
ReturnCorrelation
CLRB-94.0% 
Market (SPY)85.7%4.8%
Sector (XLV)22.9%5.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CLRB Return-68%-74%62%-89%-67%-16%-100%
Peers Return43%-20%3%78%-33%-14%20%
S&P 500 Return27%-19%24%23%16%8%98%

Monthly Win Rates [3]
CLRB Win Rate8%17%58%33%50%67% 
Peers Win Rate46%50%46%58%75%40% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
CLRB Max Drawdown-76%-84%-33%-94%-98%-45% 
Peers Max Drawdown-41%-46%-34%-26%-59%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)

How Low Can It Go

EventCLRBS&P 500
2025 US Tariff Shock
  % Loss-27.5%-18.8%
  % Gain to Breakeven37.9%23.1%
  Time to Breakeven22 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-19.2%-9.5%
  % Gain to Breakeven23.8%10.5%
  Time to Breakeven25 days24 days
2023 SVB Regional Banking Crisis
  % Loss-21.5%-6.7%
  % Gain to Breakeven27.4%7.1%
  Time to Breakeven61 days31 days
2020 COVID-19 Crash
  % Loss-59.1%-33.7%
  % Gain to Breakeven144.4%50.9%
  Time to Breakeven279 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-56.7%-19.2%
  % Gain to Breakeven131.0%23.8%
  Time to Breakeven421 days105 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-73.6%-17.9%
  % Gain to Breakeven278.4%21.8%
  Time to Breakeven195 days123 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Cellectar Biosciences's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCLRBS&P 500
2025 US Tariff Shock
  % Loss-27.5%-18.8%
  % Gain to Breakeven37.9%23.1%
  Time to Breakeven22 days79 days
2023 SVB Regional Banking Crisis
  % Loss-21.5%-6.7%
  % Gain to Breakeven27.4%7.1%
  Time to Breakeven61 days31 days
2020 COVID-19 Crash
  % Loss-59.1%-33.7%
  % Gain to Breakeven144.4%50.9%
  Time to Breakeven279 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-56.7%-19.2%
  % Gain to Breakeven131.0%23.8%
  Time to Breakeven421 days105 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-73.6%-17.9%
  % Gain to Breakeven278.4%21.8%
  Time to Breakeven195 days123 days
2008-2009 Global Financial Crisis
  % Loss-63.9%-53.4%
  % Gain to Breakeven177.3%114.4%
  Time to Breakeven169 days1085 days
Summer 2007 Credit Crunch
  % Loss-38.3%-8.6%
  % Gain to Breakeven62.0%9.5%
  Time to Breakeven662 days47 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Cellectar Biosciences's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Cellectar Biosciences (CLRB)

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs to treat various cancers. The company leverages its proprietary Phospholipid Drug Conjugate (PDC) platform, which is designed to selectively deliver therapeutic agents to cancer cells, aiming for more targeted and effective treatments.

The company's lead product candidate is CLR 131 (iopofosine I-131), which is currently undergoing multiple clinical trials for different cancer types. This includes Phase 2 studies for relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and other B-cell malignancies, as well as a Phase 2B study for r/r multiple myeloma. CLR 131 is also being evaluated in Phase 1 trials for pediatric cancers, r/r head and neck cancers, and additional r/r multiple myeloma indications. Beyond CLR 131, Cellectar is developing CLR 1900, a preclinical PDC chemotherapeutic program aimed at solid tumors. Through these programs, Cellectar Biosciences targets patients with difficult-to-treat and advanced cancers, particularly those who have relapsed or are refractory to prior therapies, and also explores applications in pediatric oncology. The company also has collaborative PDC programs with several partners to expand its pipeline.

AI Analysis | Feedback

1. **Seagen for Phospholipid Drug Conjugates (PDCs).** (Cellectar Biosciences is developing a unique drug delivery platform, PDCs, for cancer, much like Seagen pioneered Antibody-Drug Conjugates (ADCs) for cancer treatment.)

2. **Moderna, but developing a unique Phospholipid Drug Conjugate (PDC) platform for cancer.** (Similar to how Moderna is known for its innovative mRNA platform, Cellectar Biosciences is built around its novel PDC platform, specifically for treating various cancers.)

AI Analysis | Feedback

  • CLR 131 (iopofosine I-131): A lead phospholipid drug conjugate (PDC) candidate currently in various clinical trial phases for the treatment of multiple cancers, including Waldenstrom's macroglobulinemia, B-cell malignancies, multiple myeloma, pediatric cancers, and head and neck cancers.
  • CLR 1900: A PDC chemotherapeutic program that is in the preclinical development stage, aimed at treating solid tumors.
  • CLR 2000 Series: A collaborative phospholipid drug conjugate program developed in partnership with Avicenna Oncology GMBH.
  • CLR 12120 Series: A collaborative phospholipid drug conjugate program developed in partnership with Orano Med.

AI Analysis | Feedback

null

AI Analysis | Feedback

  • Curium US LLC
  • JSC Isotope

AI Analysis | Feedback

James Caruso, President, CEO and Director

Mr. Caruso was appointed President and Chief Executive Officer and a Director of Cellectar Biosciences in June 2015. He is a life sciences executive with 37 years of professional success across multinational and specialty pharmaceutical companies, mid-tier biotechnology, and medical device start-ups. Prior to Cellectar Biosciences, he co-founded Hip Innovation Technology (HIT), a private medical device company, where he served as Executive Vice President and Chief Operating Officer. He was also Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company that was acquired by Spectrum Pharmaceuticals. Additionally, Mr. Caruso served as Senior Vice President, Sales and Marketing, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. His career also includes key leadership positions at multinational pharmaceutical companies such as Novartis, BASF Pharmaceuticals-Knoll, and Bristol-Myers Squibb Company.

Chad Kolean, Chief Financial Officer

Mr. Kolean served as Chief Financial Officer for both Vivex Biologics, a regenerative medicine company, and Titan Spine.

Jarrod Longcor, Chief Operating Officer

Mr. Longcor brings over 20 years of pharmaceutical and biotech experience to Cellectar Biosciences. He previously served as Chief Business Officer for Avillion LLP, where he was responsible for executing the company's co-development partnership strategy. Before Avillion, Mr. Longcor was the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics), where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis valued over $700M.

AI Analysis | Feedback

```html

The key risk to Cellectar Biosciences is the inherent uncertainty and high failure rate associated with the development and regulatory approval of its drug candidates.

Cellectar Biosciences is a clinical biopharmaceutical company with its lead candidate, CLR 131, in Phase 2 and Phase 2B clinical studies, and other programs like CLR 1900 in preclinical development. The company's future success is primarily dependent on the successful completion of these and other clinical trials, demonstrating the safety and efficacy of its drug candidates, and subsequently obtaining necessary regulatory approvals from health authorities. The drug development process is lengthy, costly, and has a historically high attrition rate, posing a significant risk to the company's ability to bring its products to market and generate revenue.

```

AI Analysis | Feedback

null

AI Analysis | Feedback

Cellectar Biosciences (CLRB) targets several significant addressable markets for its main product candidates.

  • Waldenstrom's Macroglobulinemia: The global market for Waldenstrom's macroglobulinemia treatment was valued at approximately USD 1.2 billion. It is projected to exceed USD 1.5 billion in the future. Another estimate places the global market at approximately $800 million in 2023, expected to reach $1.3 billion by 2030.
  • B-cell Malignancies (B-cell Lymphoma): The global B-cell lymphoma market was valued at USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 7.00% from 2025 to 2034.
  • Multiple Myeloma: The global multiple myeloma therapeutics market size was estimated at USD 20.87 billion in 2023 and is projected to reach USD 30.30 billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030.
  • Pediatric Cancers: null
  • Head and Neck Cancers: The global head and neck cancer market size reached a value of USD 3,252.3 million in 2023. Looking forward, the market is expected to reach USD 7,279.8 million by 2034, exhibiting a growth rate (CAGR) of 7.6% during 2024-2034.
  • Solid Tumors: The global solid tumors market size reached a value of US$ 170.3 billion in 2023. Looking forward, the market is expected to reach US$ 375.4 billion by 2034, exhibiting a growth rate (CAGR) of 7.45% during 2024-2034.

AI Analysis | Feedback

Cellectar Biosciences (CLRB), a clinical biopharmaceutical company focused on cancer treatments, is expected to see its future revenue growth over the next 2-3 years driven primarily by the advancement and potential commercialization of its lead drug candidates and strategic partnerships.

Here are 3-5 expected drivers of future revenue growth:

  1. European Commercialization of Iopofosine I-131 for Waldenstrom's Macroglobulinemia (WM): Cellectar Biosciences is on track to submit a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) in the third quarter of 2026 for iopofosine I-131 (CLR 131) as a treatment for WM. The company anticipates potential European market approval and subsequent commercialization as early as 2027. Analysts' forecasts align with this, projecting the start of revenue generation around 2027-2028.
  2. U.S. Accelerated Approval and Launch of Iopofosine I-131 for WM: Cellectar has achieved alignment with the U.S. Food and Drug Administration (FDA) on a regulatory pathway for potential accelerated approval of iopofosine I-131 for WM. This is supported by the drug receiving Breakthrough Therapy Designation (BTD) from the FDA, which can expedite development and review. The FDA has also recommended studying the drug in post-BTKi settings, potentially broadening its U.S. market reach. The company expects to complete patient enrollment for a confirmatory study within 24 months from March 2025, which could pave the way for accelerated approval and an earlier market entry.
  3. Strategic Partnerships and Collaborations: Cellectar Biosciences is actively evaluating strategic collaborations for the commercialization of iopofosine I-131. Given the advanced stage of CLR 131 in Europe and its pursuit of accelerated approval in the U.S., new or expanded partnerships could generate revenue through upfront payments, milestone achievements, or future royalties within the 2-3 year timeframe. The company also has collaborative phospholipid drug conjugate (PDC) programs with various partners, which could contribute to revenue through similar mechanisms.
  4. Advancement of CLR 125 for Triple-Negative Breast Cancer (TNBC): The company initiated a Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer, with early data expected by mid-2026. While direct product sales from CLR 125 are unlikely within the next 2-3 years due to its early clinical stage, positive and compelling early clinical data could significantly enhance its value, potentially leading to new collaborations, licensing deals, or milestone payments that would contribute to revenue growth within the specified period.

AI Analysis | Feedback

Share Issuance

  • Cellectar Biosciences completed a $6.9 million underwritten offering on July 2, 2025.
  • The company generated approximately $2.5 million from warrant exercises on June 6, 2025.
  • In October 2025, warrant inducement and related new warrants generated approximately $5.8 million in gross proceeds.

Inbound Investments

  • Cellectar Biosciences has secured funding through 12 rounds, including 8 Post IPO rounds and 3 Grant (prize money) rounds.
  • The company completed a Post IPO funding round on September 5, 2023.
  • A Grant (prize money) funding round occurred on September 16, 2022.

Capital Expenditures

  • Cellectar Biosciences invested $61K in capital expenditures in Q4 2024.
  • Capital expenditures were approximately $5,880 for the last 12 months and -$5,880 in 2025.
  • The average capital expenditure over the past 5 years has been $285.71K.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Cellectar Biosciences Earnings Notes12/16/2025
Title
0ARTICLES

Recent Active Movers

Top Gainers

TickerCompanyMkt Cap (B)1W RtnYTD Rtn
QUREuniQure2.972.6%93.4%
BFLYButterfly Network2.356.7%134.2%
WDCWestern Digital255.241.0%333.5%
FRMIFermi6.036.7%18.8%
FCELFuelCell Energy1.235.9%228.9%
EQPTEquipmentShare.com5.535.1%-19.2%
BEBloom Energy92.732.2%278.5%
SHAZSharonAI1.329.6%0.2%
CIFRCipher Digital11.828.9%97.7%
RXTRackspace Technology1.828.9%643.6%

Top Losers

TickerCompanyMkt Cap (B)1W RtnYTD Rtn
LILAKLiberty Latin America1.0-39.5%-35.8%
LILALiberty Latin America1.0-39.2%-35.0%
LUNRIntuitive Machines2.7-25.4%40.8%
ACNAccenture79.0-23.6%-51.6%
FOXAFox22.1-23.5%-28.2%
FOXFox19.9-23.5%-27.3%
WTIW&T Offshore0.5-21.9%98.0%
MHMcGraw Hill1.8-21.7%-41.3%
PRCTPROCEPT BioRobotics1.2-21.6%-31.0%
VOYGVoyager Technologies2.2-21.5%43.7%

Top Gainers

TickerCompanyMkt Cap (B)1M RtnYTD Rtn
NVRIEnviri1.8314.1%343.2%
BFLYButterfly Network2.3117.1%134.2%
REPLReplimune0.9116.8%4.8%
AMCAMC Entertainment1.5108.1%81.4%
APPSDigital Turbine1.0106.5%72.2%
HYLNHyliion1.498.0%340.2%
QUREuniQure2.987.5%93.4%
UMACUnusual Machines0.982.9%96.1%
TWSTTwist Bioscience5.476.9%176.0%
SHAZSharonAI1.376.6%0.2%

Top Losers

TickerCompanyMkt Cap (B)1M RtnYTD Rtn
VRRMVerra Mobility0.7-66.6%-80.2%
ADCTADC Therapeutics0.2-65.3%-69.1%
CDChaince Digital0.4-49.8%-3.1%
LILAKLiberty Latin America1.0-38.4%-35.8%
SATLSatellogic0.8-37.6%222.5%
FULCFulcrum Therapeutics0.3-37.4%-67.3%
LILALiberty Latin America1.0-37.1%-35.0%
BKSYBlackSky Technology1.0-35.8%54.6%
TMCRMetals Royalty0.5-35.8%-40.4%
SOCSable Offshore1.5-33.6%12.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

CLRBVRTXATYRAVLNCNXUCOAGMedian
NameCellecta.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Price2.79451.630.4531.4513.2829.2421.26
Mkt Cap0.0114.8----57.4
Rev LTM012,218--0-0
Op Inc LTM-224,662---5--5
FCF LTM-193,710---4--4
FCF 3Y Avg-341,977----972
CFO LTM-194,241---4--4
CFO 3Y Avg-342,401----1,184

Growth & Margins

CLRBVRTXATYRAVLNCNXUCOAGMedian
NameCellecta.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Rev Chg LTM-10.1%----10.1%
Rev Chg 3Y Avg-9.9%----9.9%
Rev Chg Q-7.8%----7.8%
QoQ Delta Rev Chg LTM-1.8%----1.8%
Op Inc Chg LTM51.6%1,214.0%----632.8%
Op Inc Chg 3Y Avg2.5%364.1%----183.3%
Op Mgn LTM-38.2%----38.2%
Op Mgn 3Y Avg-24.1%----24.1%
QoQ Delta Op Mgn LTM-0.2%----0.2%
CFO/Rev LTM-34.7%----34.7%
CFO/Rev 3Y Avg-21.5%----21.5%
FCF/Rev LTM-30.4%----30.4%
FCF/Rev 3Y Avg-17.7%----17.7%

Valuation

CLRBVRTXATYRAVLNCNXUCOAGMedian
NameCellecta.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Cap0.0114.8----57.4
P/S-9.4----9.4
P/Op Inc-0.524.6----12.0
P/EBIT-0.522.7----11.1
P/E-0.626.5----12.9
P/CFO-0.627.1----13.2
Total Yield-176.2%3.8%-----86.2%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-3,397.0%1.8%-----1,697.6%
D/E0.10.0----0.1
Net D/E-0.6-0.0-----0.3

Returns

CLRBVRTXATYRAVLNCNXUCOAGMedian
NameCellecta.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
1M Rtn-8.8%4.0%-6.7%11.9%-7.8%14.9%-1.4%
3M Rtn-12.3%-1.4%-45.6%6.6%-7.8%-14.0%-10.0%
6M Rtn3.0%0.9%-35.9%6.6%-7.8%-14.0%-3.4%
12M Rtn663.3%0.7%-91.3%6.6%-7.8%-14.0%-3.5%
3Y Rtn-95.5%29.8%-81.6%6.6%-7.8%-14.0%-10.9%
1M Excs Rtn-10.8%2.0%-8.7%9.9%-9.8%12.9%-3.4%
3M Excs Rtn-25.8%-14.9%-59.1%-6.9%-21.3%-27.5%-23.6%
6M Excs Rtn-22.6%-11.0%-48.8%-3.7%-18.1%-24.3%-20.3%
12M Excs Rtn668.6%-23.2%-116.6%-18.7%-33.1%-39.4%-28.2%
3Y Excs Rtn-166.5%-39.7%-152.0%-65.0%-79.5%-85.7%-82.6%

Comparison Analyses

null

Financials

$ Mil | FY: 12/312026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End3/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/2023
Filing Date5/14/20263/4/202611/13/20258/14/20255/13/20253/13/202511/18/202410/29/20245/14/20243/27/202411/13/20238/14/2023
Key Financials Quarterly            
Total Revenue000000000000
Ebitda-6-6-5-6-6-13-13-14-12-12-9-8
Operating Income-6-6-5-6-6-13-13-14-12-13-9-8
Net Income-6-5-4-5-7-2-15-1-27-8-18-10
EPS-1.33-1.25-1.41-3.39-4.30-0.17-11.18-0.77-27.30-12.30-46.50-27.00
Key Financials TTM            
Total Revenue TTM000000000000
Ebitda TTM-22-23-30-38-46-51-51-47-42-39-34-32
Operating Income TTM-22-23-30-39-46-52-52-48-42-39-34-32
Net Income TTM-21-22-19-29-25-45-50-53-62-43-45-36
Growth Rates Quarterly            
Total Revenue Growth------------
EBITDA Growth8.7%55.5%63.8%56.1%46.7%-1.6%-41.5%-65.2%-37.5%-69.0%-20.4%-11.5%
Operating Income Growth9.5%55.3%63.6%55.9%46.7%-1.6%-41.6%-65.2%-37.9%-69.1%-20.4%-11.5%
Net Income Growth14.4%-124.8%69.7%-492.6%75.2%70.1%16.3%91.0%-270.5%24.3%-124.3%-36.9%
Margins Quarterly            
EBITDA Margin------------
Operating Income Margin------------
Net Income Margin------------
Cash & Debt            
Total Cash8131311142334264010195
Total Debt200000111111
Net Debt / (Cash)-7-13-12-11-13-23-34-25-39-9-18-5
Cash Flows Quarterly            
FCF from Operations-5-4-4-5-9-11-9-14-13-10-8-8
Cash Flows TTM            
FCF from Operations TTM-19-23-30-35-44-48-46-45-39-32-30-29
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-8.5%-8.6%-7.5%-9.5%-10.3%-21.3%-23.5%-25.2%-21.3%-28.1%-21.1%-17.3%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-8.2%-8.7%-11.6%-15.1%-18.6%-21.7%-22.8%-21.9%-18.7%-21.8%-19.0%-16.9%

Segment Financials

Net Income by Segment
$ Mil20252024
Utilizing its Phospholipid Drug Conjugates (PDC) platform to develop drugs for the treatment of-22-45
Total-22-45


Assets by Segment
$ Mil20232022202120202019
Utilizing its Phospholipid Drug Conjugates (PDC) platform to develop drugs for the treatment of1222375912
Total1222375912


Price Behavior

Price Behavior
Market Price$2.79 
Market Cap ($ Bil)0.0 
First Trading Date11/10/2005 
Distance from 52W High-71.2% 
   50 Days200 Days
DMA Price$2.84$3.47
DMA Trenddowndown
Distance from DMA-1.9%-19.6%
 3M1YR
Volatility72.5%3,171.6%
Downside Capture285.12375.06
Upside Capture122.22518.73
Correlation (SPY)34.0%9.1%
CLRB Betas & Captures as of 5/31/2026

 1M2M3M6M1Y3Y
Beta4.342.411.241.6125.065.85
Up Beta7.701.660.660.4955.257.98
Down Beta2.803.140.401.483.291.31
Up Capture399%232%134%191%5146%382%
Bmk +ve Days13283667141432
Stock +ve Days10202650109335
Down Capture330%398%203%207%225%114%
Bmk -ve Days7132757109318
Stock -ve Days7183469133383

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with CLRB
CLRB688.8%3,171.6%0.97-
Sector ETF (XLV)14.0%15.0%0.667.9%
Equity (SPY)26.5%12.4%1.618.9%
Gold (GLD)24.2%27.5%0.77-5.9%
Commodities (DBC)19.8%18.8%0.83-13.4%
Real Estate (VNQ)11.0%13.7%0.521.9%
Bitcoin (BTCUSD)-38.3%42.4%-1.022.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with CLRB
CLRB-63.5%1,416.9%0.39-
Sector ETF (XLV)5.4%14.7%0.194.9%
Equity (SPY)13.5%17.1%0.624.2%
Gold (GLD)17.1%18.3%0.76-3.8%
Commodities (DBC)7.5%19.4%0.29-5.6%
Real Estate (VNQ)1.9%18.9%0.001.7%
Bitcoin (BTCUSD)11.6%54.2%0.411.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with CLRB
CLRB-56.1%1,003.3%0.26-
Sector ETF (XLV)9.4%16.6%0.463.8%
Equity (SPY)15.3%18.0%0.733.6%
Gold (GLD)12.3%16.1%0.63-2.8%
Commodities (DBC)5.9%18.0%0.26-3.7%
Real Estate (VNQ)5.3%20.7%0.221.6%
Bitcoin (BTCUSD)60.4%66.8%1.000.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date5292026
Short Interest: Shares Quantity0.3 Mil
Short Interest: % Change Since 5152026-66.8%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest1.1 days
Basic Shares Quantity4.2 Mil
Short % of Basic Shares6.1%

Earnings Returns History

Updated 6/17/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/14/20268.8%7.8%-24.1%
3/4/20268.2%13.8%-6.7%
11/13/2025-18.0%-18.3%-8.6%
8/14/20250.0%-0.2%14.9%
5/13/2025-9.1%-3.3%61.6%
3/13/2025-5.4%21.8%-13.8%
11/18/2024-4.8%-15.1%-85.9%
8/13/20248.6%10.2%12.4%
...
SUMMARY STATS   
# Positive111012
# Negative131412
Median Positive3.5%9.0%12.1%
Median Negative-5.6%-8.5%-20.7%
Max Positive15.8%23.2%74.1%
Max Negative-18.0%-20.0%-85.9%
 Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/14/20268.8%7.8%-24.1%
3/4/20268.2%13.8%-6.7%
11/13/2025-18.0%-18.3%-8.6%
8/14/20250.0%-0.2%14.9%
5/13/2025-9.1%-3.3%61.6%
3/13/2025-5.4%21.8%-13.8%
11/18/2024-4.8%-15.1%-85.9%
8/13/20248.6%10.2%12.4%
5/14/20243.9%3.3%8.8%
3/27/2024-5.6%3.4%-21.6%
11/2/20230.8%-12.6%8.0%
8/14/20231.9%0.6%37.5%
5/4/2023-2.0%-7.3%11.3%
3/9/2023-10.5%-20.0%-26.8%
11/3/2022-6.9%-7.4%-8.3%
8/5/20223.5%17.0%4.8%
5/10/2022-8.1%-10.7%-0.8%
3/21/202215.8%23.2%17.0%
11/8/20210.7%-7.5%-25.8%
8/9/2021-1.9%-15.8%1.0%
5/10/2021-2.9%-5.1%11.8%
3/2/2021-7.5%-9.5%-19.9%
11/9/2020-3.4%-3.4%74.1%
8/10/20200.7%2.1%-24.3%
SUMMARY STATS   
# Positive111012
# Negative131412
Median Positive3.5%9.0%12.1%
Median Negative-5.6%-8.5%-20.7%
Max Positive15.8%23.2%74.1%
Max Negative-18.0%-20.0%-85.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/14/202610-Q
12/31/202503/04/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202505/13/202510-Q
12/31/202403/13/202510-K
09/30/202411/18/202410-Q
06/30/202410/29/202410-Q
03/31/202405/14/202410-Q
12/31/202303/27/202410-K
09/30/202311/13/202310-Q
06/30/202308/14/202310-Q
03/31/202305/04/202310-Q
12/31/202203/09/202310-K
09/30/202211/03/202210-Q
06/30/202208/05/202210-Q
 Collapse to Preview
Report DateFiling DateFiling
03/31/202605/14/202610-Q
12/31/202503/04/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202505/13/202510-Q
12/31/202403/13/202510-K
09/30/202411/18/202410-Q
06/30/202410/29/202410-Q
03/31/202405/14/202410-Q
12/31/202303/27/202410-K
09/30/202311/13/202310-Q
06/30/202308/14/202310-Q
03/31/202305/04/202310-Q
12/31/202203/09/202310-K
09/30/202211/03/202210-Q
06/30/202208/05/202210-Q
03/31/202205/10/202210-Q
12/31/202103/21/202210-K
09/30/202111/08/202110-Q
06/30/202108/09/202110-Q
03/31/202105/10/202110-Q
12/31/202003/02/202110-K
09/30/202011/09/202010-Q
06/30/202008/10/202010-Q
03/31/202005/07/202010-Q
12/31/201903/09/202010-K
09/30/201911/12/201910-Q
06/30/201908/12/201910-Q

Recent Forward Guidance

Updated 5/31/2026

Latest: Q1 2026 Earnings Reported 5/14/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2027 Operational Runway      

Prior: Q4 2025 Earnings Reported 3/4/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q3 2026 Cash Runway      

Insider Activity

Updated 5/11/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Longcor, JarrodChief Operating OfficerDirectBuy51120262.888,68024,99858,899Form
2Caruso, James VChief Executive OfficerDirectBuy51120262.888,68024,99858,516Form
3Neis, JohnSee FootnoteSell121620253.7019873237Form
4Caruso, James VChief Executive OfficerDirectBuy70320254.9910,00049,90058,074Form
5Longcor, JarrodChief Operating OfficerDirectBuy70320254.9910,00049,90063,712Form
 Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Longcor, JarrodChief Operating OfficerDirectBuy51120262.888,68024,99858,899Form
2Caruso, James VChief Executive OfficerDirectBuy51120262.888,68024,99858,516Form
3Neis, JohnSee FootnoteSell121620253.7019873237Form
4Caruso, James VChief Executive OfficerDirectBuy70320254.9910,00049,90058,074Form
5Longcor, JarrodChief Operating OfficerDirectBuy70320254.9910,00049,90063,712Form
6Kolean, Chad JChief Financial OfficerDirectBuy70320254.995,00024,95032,026Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/18/2026